Four Pharmaceutical Companies—Haichen Pharma, Wismed, GemPharmatech, and TBP Biosciences—Report Revenue and Profit Growth in Q1-Q3 2025

　　【Pharmaceutical Network Industry DynamicsAccording to the review, on October 22, more than 10 pharmaceutical companies released their 2025 third-quarter earnings reports. Among them, about four pharmaceutical companies achieved double growth in revenue and profit, including Nanjing Haichen Pharmaceutical Co., Ltd., VISHEE, Yaokang Biotech, and Amoytop Biotech.
 

According to the Q3 2025 report disclosed by Nanjing Haichen Pharmaceutical Co., Ltd., the company's revenue for the first three quarters of this year increased by 30.8% year-on-year, reaching 472 million yuan; the net profit attributable to shareholders increased by 16.2% year-on-year, reaching 32.68 million yuan; and the non-recurring net profit attributable to shareholders increased by 1.6% year-on-year, reaching 29.54 million yuan.
 

Data shows that the main business of Nanjing Haichen Pharmaceutical Co., Ltd. involves chemical preparations,Active Pharmaceutical IngredientsAndIntermediateResearch and development, production, and sales. The company's core product, Injectable Landiolol Hydrochloride (a third-generation beta-blocker), has achieved considerable sales, with cardiovascular drugs becoming the main revenue driver.
 

Analysis points out that the smooth progress of Nanjing Haichen Pharmaceutical Co., Ltd.'s R&D projects, especially the clinical trials of the anti-tumor drug HC-1119 (AR antagonist), as well as the acquisition of innovative drug resources through international cooperation, has unleashed the potential of innovative drugs. It is reported that the company's anti-tumor drug HC-1119 has successfully entered Phase I clinical trials and plans to initiate Phase III trials in 2026, with a potential market size expected to exceed 5 billion yuan, posing strong competition to Pfizer's Enzalutamide. Meanwhile, the company is also actively advancing the development of Cetrorelix Acetate for assisted reproductive use, with the application for production approval already on the agenda, aligning closely with current fertility policy support. In addition, the company is actively seeking international cooperation by holding a 90% stake in Italy’s NMS Group, gaining access to early-stage R&D resources for anti-tumor innovative drugs, thereby forming a "generic and innovative combination" R&D model.
 

VISHEE Achieves Revenue of 115 Million Yuan in the First Three Quarters of This Year, Increasing by 14.87% Year-on-Year; Net Profit Attributable to Parent Company is 32.824 Million Yuan, with a Year-on-Year Increase of 14.99%, and Non-Recurring Net Profit is 30.0288 Million Yuan, Growing by 21.61% Year-on-Year.
 

VISHEE's main business is the research and development, production, and sales of medical devices. The company's products mainly include electrical stimulation, magnetic stimulation, electrophysiological, and rehabilitation categories.RobotMedical devices for rehabilitation and related products, with application areas covering multiple niche fields such as pelvic floor and postpartum rehabilitation, neurological rehabilitation, psychiatric rehabilitation, and pediatric rehabilitation. Since the beginning of this year, whether in a single quarter or on a semi-annual basis, VISHEE has delivered financial results showing double growth in both revenue and net profit.
 

It is reported that VISHEE is tapping into new niche markets. In its semi-annual report for 2025, the company explicitly stated that in the second half of the year, it would deepen its strategy of "focusing on core rehabilitation businesses while expanding into emerging businesses." While enriching its rehabilitation product portfolio, VISHEE will increase its investment in emerging sectors such as photomedicine aesthetics and urology. Currently, VISHEE has entered the field of laser treatment for urology through the acquisition of Creda Laser. In the field of medical aesthetics, VISHEE has laid out products like body-sculpting magnets, picosecond lasers, and radiofrequency devices. The company aims to accelerate the commercialization of its aesthetic products, expand large-scale sales of three major aesthetic solutions—skin, body, and intimate care—and create a new growth curve.
 

Pharmaceutical Health Biotech Achieves Operating Revenue of 576 Million Yuan in the First Three Quarters of This Year, a Year-on-Year Increase of 12.92%; Net Profit Attributable to Parent Company Reached 110 Million Yuan, a Year-on-Year Increase of 11.90%; Non-Recurring Net Profit Reached 92.7851 Million Yuan, a Year-on-Year Increase of 29.21%.
 

Data shows that Pharmakon Bio mainly operates in spotted mice, immunodeficient mouse models, humanized mouse models, disease mouse models, germ-free mouse models, basic strains, and other models. Regarding the growth in performance, Pharmakon Bio stated that the increase in net profit during the reporting period was primarily due to increased production capacity, as well as business growth driven by the expansion of domestic and international markets.
 

Amoytop Biotech's revenue in the first three quarters of this year was 2.48 billion yuan, representing a year-on-year increase of 26.85%; the net profit attributable to shareholders was 666 million yuan, up 20.21% year-on-year; the non-recurring net profit attributable to shareholders was 673 million yuan, increasing by 15.91% year-on-year.
 

Data shows that Amoytop Biotech mainly engages in the research, development, production, and sales of recombinant proteins and their long-acting modified drugs. Focusing on the development of immune-related cytokine drugs, the company is committed to providing better solutions for treatment areas such as liver diseases, tumors, and metabolic-related conditions. It has now become a key player in China’s polyethylene glycol (PEG) protein long-acting drug sector. Currently, Amoytop Biotech has established an innovative platform technology centered on PEG long-acting drugs. Several PEG long-acting Class 1 new drugs have been launched, including Pegasys, Yipesheen, and Peijin. Data indicates that from 2018 to 2024, Amoytop Biotech's operating performance maintained annual growth, with revenue increasing from 448 million yuan to 2.817 billion yuan, and net profit rising from 16 million yuan to 827 million yuan.
 

Disclaimer: In any case, the information or opinions expressed in this article do not constitute investment advice to any person.